These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 16935768)

  • 1. Long-term primary medical therapy with somatostatin analogs in acromegaly.
    Su DH; Liao KM; Chen HW; Chang TC
    J Formos Med Assoc; 2006 Aug; 105(8):664-9. PubMed ID: 16935768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
    Colao A; Pivonello R; Auriemma RS; Briganti F; Galdiero M; Tortora F; Caranci F; Cirillo S; Lombardi G
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2112-8. PubMed ID: 16537687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
    Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and limits of somatostatin analogs.
    Petersenn S
    J Endocrinol Invest; 2005; 28(11 Suppl International):53-7. PubMed ID: 16625846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
    Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
    Cannavò S; Squadrito S; Curtò L; Almoto B; Trimarchi F
    Horm Metab Res; 2001 Oct; 33(10):618-24. PubMed ID: 11607883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.
    Tutuncu Y; Berker D; Isik S; Ozuguz U; Akbaba G; Kucukler FK; Aydin Y; Guler S
    Pituitary; 2012 Sep; 15(3):398-404. PubMed ID: 21863263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal.
    Auriemma RS; Galdiero M; Grasso LF; Vitale P; Cozzolino A; Lombardi G; Colao A; Pivonello R
    Eur J Endocrinol; 2010 May; 162(5):993-9. PubMed ID: 20156970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma.
    Li ZQ; Quan Z; Tian HL; Cheng M
    J Int Med Res; 2012; 40(2):517-24. PubMed ID: 22613412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
    Casarini AP; Pinto EM; Jallad RS; Giorgi RR; Giannella-Neto D; Bronstein MD
    J Endocrinol Invest; 2006 Oct; 29(9):826-30. PubMed ID: 17114915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
    Yin J; Su CB; Xu ZQ; Yang Y; Ma WB; Tao W; Yang Z; Xia XW
    Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
    Colao A; Auriemma RS; Pivonello R
    Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.